Compare SBI & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBI | CSBR |
|---|---|---|
| Founded | 1992 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 90.0M |
| IPO Year | N/A | 1986 |
| Metric | SBI | CSBR |
|---|---|---|
| Price | $7.76 | $6.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 39.5K | 9.1K |
| Earning Date | 01-01-0001 | 12-15-2025 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $56,878,000.00 |
| Revenue This Year | N/A | $7.31 |
| Revenue Next Year | N/A | $12.01 |
| P/E Ratio | ★ N/A | $31.49 |
| Revenue Growth | N/A | ★ 10.11 |
| 52 Week Low | $6.96 | $4.61 |
| 52 Week High | $8.00 | $11.99 |
| Indicator | SBI | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 58.38 |
| Support Level | $7.76 | $6.16 |
| Resistance Level | $7.84 | $6.43 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.67 | 73.08 |
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.